Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Migraine Headaches
Interventions: Aspirin, Acetaminophen, Caffeine pills, Prochlorperazine 10mg; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Erectile Dysfunction
Interventions: Platelet rich plasma, Placebo Sham Injection; Biological · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: Endotoxin, Placebo; Biological · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone Bromide, Placebo-Normal Saline; Drug
Lead sponsor: St. John Health System, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Forward Head Posture With Associated Episodic Headache Disorder
Interventions: Botox, Saline; Drug
Lead sponsor: The Research Center of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Oceanside, California

Conditions: Pain, Postoperative
Interventions: NMDA active, Steroid active, NMDA placebo, Steroid placebo; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions: Hydroxocobalamin, Methylene Blue, Normal saline; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pachyonychia Congenita
Interventions: TD101, Normal saline (placebo); Drug
Lead sponsor: Pachyonychia Congenita Project; Other
Eligibility: 10 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions: Exparel (Bupivacaine Liposome), Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Meniscus Tear, Meniscus Lesion, Cartilage Injury
Interventions: Ceftriaxone, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pain, Postoperative
Interventions: Ketorolac Tromethamine, Morphine Sulfate, Intravenous Placebo for NTM-001, IV Placebo for Morphine; Drug · Other
Lead sponsor: Neumentum, Inc.; Other
Eligibility: 18 Years to 64 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Sun City, Arizona • Bakersfield, California • Canoga Park, California + 7 more

Conditions: Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
Interventions: LJPC-501, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 52
States / cities: Mobile, Alabama • Phoenix, Arizona • Loma Linda, California + 39 more

Conditions: Pruritus Caused by Drug
Interventions: Ondansetron 8mg; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions: IK-5001, Saline Solution; Device
Lead sponsor: Bellerophon BCM LLC; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more

Conditions: ATIII Deficiency
Interventions: Anti-thrombin III, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: Up to 7 Months
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide, Darolutamide during Lead-in Period, Lead-in Darolutamide followed by Radium-223/Darolutamide, Lead-in Darolutamide followed by Placebo/Darolutamide; Drug
Lead sponsor: MANA RBM; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Myrtle Beach, South Carolina

Conditions: Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL); Drug
Lead sponsor: University of Arizona; Other
Eligibility: Up to 18 Hours
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Warts
Interventions: Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline; Biological · Other
Lead sponsor: Western Institute for Veterans Research; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Asthma
Interventions: Magnesium Sulfate, Heptahydrate, 0.9% saline; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Pediatric Burns
Interventions: magnesium sulfate, Normal Saline (0.9% NaCl); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Placebo - Control, Experimental
Interventions: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Drug
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Multiple Sclerosis
Interventions: Rituximab, Glatiramer Acetate, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Knee Osteoarthritis, Synovitis of Knee
Interventions: 4P004, Placebo (NaCl 0.9%); Drug
Lead sponsor: 4Moving Biotech; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts

Conditions: HIV Infections
Interventions: VRC01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more

Search by objective public record fields.

Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine

The Role of Platelet Rich Plasma for Erectile Dysfunction

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

PROPER Trial of Pain and Inflammation After Knee Arthroscopy

Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Timely Intravenous Magnesium for Asthma in Children

Magnesium Sulfate in Pediatric Burn Dressing Changes

What is the Role of Type III/IV Muscle Afferents in Airway Resistance and Thermoregulatory Responses to Exercise?

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)